





DATE	ACTION/DESCRIPTION
10/18/2021	Increlex policy creation
09/15/2023	Added in consultation with option to prescriber specialty; added documentation of pretreatment height; added no history of active malignancy; removed not being treated with growth hormone therapy from reauthorization criteria.

References:

1. Increlex [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; December 2019
2. Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for growth hormone and insulinlike growth factor-1 treatment in children